Natera Inc (NASDAQ:NTRA) saw a large growth in short interest in September. As of September 28th, there was short interest totalling 1,814,855 shares, a growth of 81.4% from the September 14th total of 1,000,242 shares. Based on an average trading volume of 1,109,863 shares, the days-to-cover ratio is presently 1.6 days. Currently, 4.4% of the shares of the company are short sold.

Shares of NTRA opened at $20.77 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of -3.32. Natera has a 1 year low of $8.60 and a 1 year high of $29.62. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -8.70 and a beta of 2.24.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.55). Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The business had revenue of $63.07 million during the quarter, compared to analyst estimates of $61.71 million. During the same period last year, the firm posted ($0.55) EPS. The company’s revenue was up 20.6% on a year-over-year basis. Analysts forecast that Natera will post -2.07 earnings per share for the current fiscal year.

In related news, CEO Matthew Rabinowitz sold 185,163 shares of the stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $25.13, for a total value of $4,653,146.19. Following the completion of the sale, the chief executive officer now directly owns 1,701,686 shares of the company’s stock, valued at approximately $42,763,369.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Steven Leonard Chapman sold 35,000 shares of the stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $23.76, for a total transaction of $831,600.00. Following the completion of the sale, the chief operating officer now directly owns 19,022 shares of the company’s stock, valued at $451,962.72. The disclosure for this sale can be found here. Insiders sold a total of 1,813,321 shares of company stock valued at $44,508,270 over the last three months. 13.18% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Tygh Capital Management Inc. grew its holdings in Natera by 32.3% during the 2nd quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock valued at $5,647,000 after buying an additional 73,301 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new position in shares of Natera during the 2nd quarter valued at approximately $572,000. EAM Investors LLC bought a new position in shares of Natera during the 2nd quarter valued at approximately $3,868,000. Sei Investments Co. bought a new position in shares of Natera during the 2nd quarter valued at approximately $928,000. Finally, Swiss National Bank boosted its position in shares of Natera by 27.1% during the 2nd quarter. Swiss National Bank now owns 60,900 shares of the medical research company’s stock valued at $1,146,000 after acquiring an additional 13,000 shares during the last quarter. 66.31% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on the stock. Robert W. Baird increased their price objective on shares of Natera from $17.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, June 28th. Craig Hallum set a $23.00 price objective on shares of Natera and gave the company a “positive” rating in a report on Thursday, June 28th. ValuEngine raised shares of Natera from a “buy” rating to a “strong-buy” rating in a report on Friday, June 22nd. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a report on Thursday, June 21st. Finally, BidaskClub lowered shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $26.13.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: Balance Sheet

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.